Written answers
Tuesday, 24 February 2015
Department of Health
Drugs Payment Scheme Coverage
Finian McGrath (Dublin North Central, Independent)
Link to this: Individually | In context | Oireachtas source
444. To ask the Minister for Health the position regarding a treatment for the disease paroxysmal nocturnal hemoglobinuria in respect of a person (details supplied) in County Donegal; and if he will make a statement on the matter. [7930/15]
Kathleen Lynch (Cork North Central, Labour)
Link to this: Individually | In context | Oireachtas source
The HSE has taken a decision to extend access to Eculizumab (Soliris) for sufferers of the diseases Paroxysmal Nocturnal Hemoglobinuria and atypical Haemolytic Uraemic Syndrome.
Due to the exorbitant cost of this drug the provision of Eculizumab for patients will be on a case by case basis and on the basis of clinical need.
Treating clinicians can apply to the HSE's Medicines Management Programme in order to commence a screening process for their respective patients.
No comments